US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Emera Inc.

50.08

-1.7000-3.28%

Post-market: 51.050.9700+1.94%19:30 EDT

Volume:487.92K

Turnover:24.66M

Market Cap:15.31B

PE:22.46

High:51.91

Open:51.91

Low:50.03

Close:51.78

52wk High:55.49

52wk Low:45.77

Shares:305.78M

Float Shares:305.78M

Volume Ratio:1.75

T/O Rate:0.16%

Dividend:2.12

Dividend Rate:4.22%

EPS(TTM):2.23

EPS(LYR):2.47

ROE:7.56%

ROA:2.91%

PB:1.63

PE(LYR):20.32

Loading ...

Overview Company News Filings

Oculis to Present at Upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Oculis to Present at Upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Earning Preview: Emera Inc. this quarter’s revenue is expected to increase by 35.49%, and institutional views are Neutral

OS Therapies Gains EMA Rolling Review for OST-HER2

Press Release: Teva Delivers Strong Q1 2026 Results Driven by Innovative Portfolio Growth and Disciplined Execution

Emera Inc : Barclays Initiates Coverage With Equal-Weight Rating and Target Price $53

THOMSON REUTERS

Emera initiated with an Equal Weight at Barclays

Analysts Have Conflicting Sentiments on These Utilities Companies: Emera (EMA), Origin Energy Limited (OtherOGFGF) and Clearway Energy (CWEN)

A Look At Arrowhead Pharmaceuticals (ARWR) Valuation After EMA CHMP Backs REDEMPLO For FCS

Simply Wall St.

Novartis Rhapsido® receives European Commission approval as first oral targeted treatment for chronic spontaneous urticaria

Clinuvel Unlikely to Seek Scenesse's Vitiligo Approval Before Phase 3 Completion, Says Jefferies

MT Newswires Live

PYC Wins EMA Orphan Status for RP11 Gene Therapy Candidate VP-001

J.P. Morgan Reaffirms Their Hold Rating on Emera (EMA)

How Investors Are Reacting To Clinuvel Pharmaceuticals (ASX:CUV) EMA Guidance On SCENESSE Vitiligo Trial Design

Simply Wall St.

Novartis receives positive CHMP opinion for Itvisma® for spinal muscular atrophy (SMA)

Ema: Chmp Recommended Extensions of Indication for Nine Medicines Including Comirnaty

THOMSON REUTERS

CLINUVEL receives final EMA scientific advice for pivotal Phase III vitiligo study

Clinuvel Pharmaceuticals Set for Phase 3 Vitiligo Study After Final Advice From European Medicines Agency

MT Newswires Live

Clinuvel Secures EMA Guidance for Pivotal Vitiligo Trial of SCENESSE

Press Release: Ipsen delivers strong sales in the first quarter of 2026 and confirms its full-year guidance

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/EMA/news?page=9"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"EMA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EMA\",,,,,undefined,":{"symbol":"EMA","market":"US","secType":"STK","nameCN":"Emera Inc.","latestPrice":50.08,"timestamp":1787342400000,"preClose":51.78,"halted":0,"volume":487921,"hourTrading":{"tag":"盘后","latestPrice":51.05,"preClose":50.08,"latestTime":"19:30 EDT","volume":175258,"amount":8787992.254964,"timestamp":1787355005298,"change":0.97,"changeRate":0.019369,"amplitude":0.019369},"delay":0,"changeRate":-0.03283120896098885,"floatShares":305783111,"shares":305783111,"eps":2.229761,"marketStatus":"Not Yet Opened","change":-1.7,"latestTime":"08-21 16:00:00 EDT","open":51.91,"high":51.91,"low":50.025,"amount":24657789.365397997,"amplitude":0.036404,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.229761,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":0,"adr":0,"exchange":"NYSE","adjPreClose":51.78,"dividendRate":0.042108,"preHourTrading":{"tag":"盘前","latestPrice":52.07,"preClose":51.78,"latestTime":"09:00 EDT","volume":9,"amount":465.57171,"timestamp":1787317237082,"change":0.29,"changeRate":0.005601,"amplitude":0.030707},"postHourTrading":{"tag":"盘后","latestPrice":51.05,"preClose":50.08,"latestTime":"19:30 EDT","volume":175258,"amount":8787992.254964,"timestamp":1787355005298,"change":0.97,"changeRate":0.019369,"amplitude":0.019369},"volumeRatio":1.7497389305446422,"impliedVol":0.0649,"impliedVolPercentile":0.1633},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EMA\",,,,,undefined,":{"symbol":"EMA","floatShares":305783111,"roa":"2.91%","roe":"7.56%","lyrEps":2.465138,"volumeRatio":1.7497389305446422,"shares":305783111,"dividePrice":2.115633,"high":51.91,"amplitude":0.036404,"preClose":51.78,"low":50.025,"week52Low":45.77,"pbRate":"1.63","psRate":"2.37","week52High":55.49,"institutionHeld":0,"latestPrice":50.08,"eps":2.229761,"divideRate":0.042245,"volume":487921,"delay":0,"ttmEps":2.229761,"open":51.91,"prevYearClose":49.24,"prevWeekClose":51.51,"prevMonthClose":53.89,"prevQuarterClose":53.02,"fiveDayClose":51.51,"twentyDayClose":54.95,"sixtyDayClose":53.63,"dividendPayoutRate":0.8394110571990734,"dividendFrequency":"Q","dividendGrowthYears":0,"fiveYearAvgDividendRate":0.04206805783252231},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EMA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-07","symbol":"EMA","fiscalQuarterEnding":"2026/06","expectedEps":0.51,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786075200000,"reportTimeType":"pre","actualEps":0.5},{"date":"2026-08-03","symbol":"EMA","amount":0.7325,"announcedDate":"2026-07-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-03","defaultRemindTime":1785763800000,"name":"Emera Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-17","payableDate":"2026-08-03","currency":"CAD","dateTimestamp":1785729600000,"payDate":"2026-08-17"},{"market":"US","date":"2026-05-08","symbol":"EMA","fiscalQuarterEnding":"2026/03","expectedEps":0.89,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778212800000,"reportTimeType":"pre","actualEps":1},{"date":"2026-05-01","symbol":"EMA","amount":0.7325,"announcedDate":"2026-04-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-05-01","defaultRemindTime":1777642200000,"name":"Emera Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-05-15","payableDate":"2026-05-01","currency":"CAD","dateTimestamp":1777608000000,"payDate":"2026-05-15"},{"market":"US","date":"2026-02-23","symbol":"EMA","fiscalQuarterEnding":"2025/12","expectedEps":0.43,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1771822800000,"reportTimeType":"pre","actualEps":0.4}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EMA\",market:\"US\",,,undefined,":[{"executeDate":"2016-10-28","recordDate":"2016-11-01","paymentDate":"2016-11-15","value":0.3880294,"currency":"USD"},{"executeDate":"2025-08-01","recordDate":"2025-08-01","paymentDate":"2025-08-15","value":0.725,"currency":"CAD"},{"executeDate":"2025-10-31","recordDate":"2025-10-31","paymentDate":"2025-11-14","value":0.7325,"currency":"CAD"},{"executeDate":"2026-01-30","recordDate":"2026-01-30","paymentDate":"2026-02-13","value":0.7325,"currency":"CAD"},{"executeDate":"2026-05-01","recordDate":"2026-05-01","paymentDate":"2026-05-15","value":0.7325,"currency":"CAD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"EMA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":1,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":1,"analysts":1,"updateTime":1778299200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/EMA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"EMA","date":"2026-08-21","current":22.459806,"percent":0.843648,"low":16.637027,"twenty":17.635291,"median":20.20188,"eighty":21.05159,"high":22.07626,"avg":19.793468,"sd":1.503181,"marketCap":15955602988.26},"quantilePoints":[{"date":"2025-05-30","current":19.76944,"twenty":19.76944,"median":19.76944,"eighty":19.76944,"marketCap":13505496352.43},{"date":"2025-06-06","current":19.324012,"twenty":19.535669,"median":19.692043,"eighty":19.76944,"marketCap":13350532994.37},{"date":"2025-06-13","current":19.308216,"twenty":19.137627,"median":19.324012,"eighty":19.722054,"marketCap":13371262392.6},{"date":"2025-06-20","current":19.245035,"twenty":19.160372,"median":19.387193,"eighty":19.674036,"marketCap":13211518175.96},{"date":"2025-06-27","current":19.308216,"twenty":19.224185,"median":19.382455,"eighty":19.560942,"marketCap":13348226238.04},{"date":"2025-07-03","current":19.469329,"twenty":19.242508,"median":19.399829,"eighty":19.679723,"marketCap":13533023992.92},{"date":"2025-07-11","current":19.753645,"twenty":19.282944,"median":19.43142,"eighty":19.706259,"marketCap":13611556279.78},{"date":"2025-07-18","current":19.592532,"twenty":19.308216,"median":19.502499,"eighty":19.712577,"marketCap":13439260670.95},{"date":"2025-07-25","current":20.116937,"twenty":19.317694,"median":19.614646,"eighty":19.767545,"marketCap":13920070443.21},{"date":"2025-08-01","current":20.552889,"twenty":19.356234,"median":19.663612,"eighty":19.931816,"marketCap":14004388886.88},{"date":"2025-08-08","current":20.884591,"twenty":19.383402,"median":19.706259,"eighty":20.124519,"marketCap":14315223696.17},{"date":"2025-08-15","current":20.686356,"twenty":19.389088,"median":19.714157,"eighty":20.375981,"marketCap":14241020029.57},{"date":"2025-08-22","current":21.111677,"twenty":19.401724,"median":19.753645,"eighty":20.511821,"marketCap":14434555399.62},{"date":"2025-08-29","current":20.468969,"twenty":19.420679,"median":19.785235,"eighty":20.581071,"marketCap":14130173597.74},{"date":"2025-09-05","current":20.484722,"twenty":19.429525,"median":19.883167,"eighty":20.585711,"marketCap":14060435241.25},{"date":"2025-09-12","current":20.283088,"twenty":19.441529,"median":20.015847,"eighty":20.549566,"marketCap":13928376571.28},{"date":"2025-09-19","current":19.923928,"twenty":19.461747,"median":20.073945,"eighty":20.542062,"marketCap":13714455884.59},{"date":"2025-09-26","current":20.585539,"twenty":19.495865,"median":20.087756,"eighty":20.542062,"marketCap":14040465233.16},{"date":"2025-10-03","current":21.108526,"twenty":19.558414,"median":20.183278,"eighty":20.617044,"marketCap":14341364686.36},{"date":"2025-10-10","current":21.127429,"twenty":19.601378,"median":20.281209,"eighty":20.758818,"marketCap":14318469638.17},{"date":"2025-10-17","current":21.666169,"twenty":19.623491,"median":20.300416,"eighty":20.797254,"marketCap":14653790731.95},{"date":"2025-10-24","current":21.757535,"twenty":19.646868,"median":20.374454,"eighty":20.916344,"marketCap":14770054950.94},{"date":"2025-10-31","current":21.360568,"twenty":19.663296,"median":20.386244,"eighty":21.06631,"marketCap":14513331426.12},{"date":"2025-11-07","current":21.272354,"twenty":19.674036,"median":20.41226,"eighty":21.097184,"marketCap":14296037747.86},{"date":"2025-11-14","current":17.374062,"twenty":19.601378,"median":20.386244,"eighty":21.06631,"marketCap":14568586353.81},{"date":"2025-11-21","current":17.212836,"twenty":19.441529,"median":20.374454,"eighty":21.041735,"marketCap":14368588864.66},{"date":"2025-11-28","current":17.407331,"twenty":19.394143,"median":20.301992,"eighty":21.030393,"marketCap":14577653448.13},{"date":"2025-12-05","current":16.921093,"twenty":19.311375,"median":20.282148,"eighty":21.003928,"marketCap":14257439118.84},{"date":"2025-12-12","current":16.693329,"twenty":19.18059,"median":20.230664,"eighty":20.983135,"marketCap":14234564864},{"date":"2025-12-19","current":17.167393,"twenty":17.900621,"median":20.102346,"eighty":20.957301,"marketCap":14657419004.37},{"date":"2025-12-26","current":17.216186,"twenty":17.458514,"median":20.073945,"eighty":20.944699,"marketCap":14789996894.17},{"date":"2026-01-02","current":17.370269,"twenty":17.373303,"median":20.0392,"eighty":20.932097,"marketCap":14871263471.89},{"date":"2026-01-09","current":17.43447,"twenty":17.368214,"median":19.923928,"eighty":20.903742,"marketCap":14773589152.84},{"date":"2026-01-16","current":17.439606,"twenty":17.353836,"median":19.83736,"eighty":20.887161,"marketCap":14748903694.51},{"date":"2026-01-23","current":17.57828,"twenty":17.358457,"median":19.76786,"eighty":20.862056,"marketCap":14967122519.73},{"date":"2026-01-30","current":17.452446,"twenty":17.36616,"median":19.731531,"eighty":20.822459,"marketCap":15149245081.41},{"date":"2026-02-06","current":17.639913,"twenty":17.358457,"median":19.706259,"eighty":20.792844,"marketCap":15150466223.22},{"date":"2026-02-13","current":17.632209,"twenty":17.329694,"median":19.687304,"eighty":20.780241,"marketCap":15197950382.19},{"date":"2026-02-20","current":18.01228,"twenty":17.336884,"median":19.662032,"eighty":20.776461,"marketCap":15461241242.05},{"date":"2026-02-27","current":19.370854,"twenty":17.349212,"median":19.603589,"eighty":20.77079,"marketCap":15419204876.87},{"date":"2026-03-06","current":19.860551,"twenty":17.357687,"median":19.614646,"eighty":20.758818,"marketCap":15772457447.89},{"date":"2026-03-13","current":20.172176,"twenty":17.364105,"median":19.663612,"eighty":20.731723,"marketCap":16126249798.12},{"date":"2026-03-20","current":19.982975,"twenty":17.371786,"median":19.706259,"eighty":20.697698,"marketCap":15868293252.05},{"date":"2026-03-27","current":19.866116,"twenty":17.374599,"median":19.676248,"eighty":20.661152,"marketCap":15623406729.11},{"date":"2026-04-02","current":20.186088,"twenty":17.375919,"median":19.706259,"eighty":20.620195,"marketCap":15797694590.77},{"date":"2026-04-10","current":20.433719,"twenty":17.383333,"median":19.710303,"eighty":20.603182,"marketCap":16095943521.79},{"date":"2026-04-17","current":20.225489,"twenty":17.405284,"median":19.739002,"eighty":20.583555,"marketCap":16062393790.34},{"date":"2026-04-24","current":20.11598,"twenty":17.412759,"median":19.756565,"eighty":20.571074,"marketCap":16011506016.84},{"date":"2026-05-01","current":20.349038,"twenty":17.435497,"median":19.769087,"eighty":20.551228,"marketCap":16279588937.86},{"date":"2026-05-08","current":20.003663,"twenty":17.442174,"median":19.801031,"eighty":20.543322,"marketCap":15972071463.03},{"date":"2026-05-15","current":20.526748,"twenty":17.453473,"median":19.863334,"eighty":20.551228,"marketCap":15993082457.11},{"date":"2026-05-22","current":20.821212,"twenty":17.457768,"median":19.873689,"eighty":20.574777,"marketCap":16159791825.34},{"date":"2026-05-29","current":20.784047,"twenty":17.458514,"median":19.874498,"eighty":20.606796,"marketCap":16109213261.77},{"date":"2026-06-05","current":20.455276,"twenty":17.46015,"median":19.931505,"eighty":20.606796,"marketCap":15744335184.44},{"date":"2026-06-12","current":20.798341,"twenty":17.481546,"median":19.990575,"eighty":20.612514,"marketCap":15890994194.64},{"date":"2026-06-18","current":20.901261,"twenty":17.493192,"median":20.015847,"eighty":20.650154,"marketCap":15823421326.33},{"date":"2026-06-26","current":21.595968,"twenty":17.496103,"median":20.061717,"eighty":20.767009,"marketCap":16281617755.86},{"date":"2026-07-02","current":21.507343,"twenty":17.504259,"median":20.064683,"eighty":20.784032,"marketCap":16222688501.02},{"date":"2026-07-10","current":21.544508,"twenty":17.526194,"median":20.082188,"eighty":20.821212,"marketCap":16271827884.13},{"date":"2026-07-17","current":21.936175,"twenty":17.541814,"median":20.087829,"eighty":20.898969,"marketCap":16718811747.19},{"date":"2026-07-24","current":22.07626,"twenty":17.564926,"median":20.116937,"eighty":20.951,"marketCap":16761941188.16},{"date":"2026-07-31","current":21.66744,"twenty":17.586675,"median":20.124404,"eighty":21.004011,"marketCap":16545696607.24},{"date":"2026-08-07","current":20.666833,"twenty":17.604226,"median":20.156816,"eighty":21.026741,"marketCap":15758445214.07},{"date":"2026-08-14","current":21.122954,"twenty":17.619883,"median":20.180562,"eighty":21.040346,"marketCap":15758083883.88},{"date":"2026-08-21","current":21.131815,"twenty":17.635291,"median":20.20188,"eighty":21.05159,"marketCap":15955602988.26}],"updateTime":1787530397351},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"EMA\",pageSize:20,pageCount:9,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2632618574","title":"Oculis to Present at Upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2632618574","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632618574?lang=en_us&edition=fundamental","pubTime":"2026-05-01 16:00","pubTimestamp":1777622400,"startTime":"0","endTime":"0","summary":"Latest findings from the DME AWARE Delphi Study on unmet needs in diabetic macular edema (DME) management highlighting the need for non-invasive therapeutic options to be presented by Baruch Kupperman","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/01/3285711/0/en/Oculis-to-Present-at-Upcoming-Association-for-Research-in-Vision-and-Ophthalmology-ARVO-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ON","LU1854103824.USD","LU0124384867.USD","OCS","BK4007","IE00BFMHRM44.USD","BK4081","LU1861219969.SGD","LU2360107325.USD","IE00BZ199S13.USD","BK4141","LU0724618433.USD","LU1720051017.SGD","LU1548497426.USD","LU1978683503.SGD","LU1861220033.SGD","IE00BD6J9T35.USD","LU1854104046.USD","BK4605","LU2357305700.SGD","LU1720051108.HKD","LU1861214812.USD","LU2298322129.HKD","EMA","LU0348723411.USD","LU1861215975.USD","BK4585","BK4588","BK4512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632572618","title":"Oculis to Present at Upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2632572618","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632572618?lang=en_us&edition=fundamental","pubTime":"2026-05-01 16:00","pubTimestamp":1777622400,"startTime":"0","endTime":"0","summary":"ZUG, Switzerland, May  01, 2026 (GLOBE NEWSWIRE) -- Latest findings from the DME AWARE Delphi Study on unmet needs in diabetic macular edema (DME) management highlighting the need for non-invasive the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/01/3285712/0/en/Oculis-to-Present-at-Upcoming-Association-for-Research-in-Vision-and-Ophthalmology-ARVO-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ON","BK4081","LU1861220033.SGD","BK4585","OCS","IE00BD6J9T35.USD","LU1720051108.HKD","LU1978683503.SGD","BK4512","EMA","LU1861219969.SGD","LU1720051017.SGD","BK4141","BK4588","BK4605","LU0124384867.USD","LU1861214812.USD","LU1548497426.USD","LU2357305700.SGD","LU1854104046.USD","LU2360107325.USD","LU0724618433.USD","LU1861215975.USD","IE00BFMHRM44.USD","IE00BZ199S13.USD","LU2298322129.HKD","LU1854103824.USD","BK4007","LU0348723411.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111536925","title":"Earning Preview: Emera Inc. this quarter’s revenue is expected to increase by 35.49%, and institutional views are Neutral","url":"https://stock-news.laohu8.com/highlight/detail?id=1111536925","media":"Earnings Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111536925?lang=en_us&edition=fundamental","pubTime":"2026-05-01 09:23","pubTimestamp":1777598598,"startTime":"0","endTime":"0","summary":"Abstract Emera Inc. is scheduled to report quarterly results on May 8, 2026 Pre-Market; this preview summarizes the latest actuals and current-quarter forecasts on revenue, profitability, and EPS,...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Earning Preview: Emera Inc. this quarter’s revenue is expected to increase by 35.49%, and institutional views are Neutral","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632664219","title":"OS Therapies Gains EMA Rolling Review for OST-HER2","url":"https://stock-news.laohu8.com/highlight/detail?id=2632664219","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632664219?lang=en_us&edition=fundamental","pubTime":"2026-05-01 05:18","pubTimestamp":1777583885,"startTime":"0","endTime":"0","summary":"OS Therapies Incorporated ( ($OSTX) ) has issued an announcement. On April 30, 2026, OS Therapies announced that the European Medicines Agency has ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/os-therapies-gains-ema-rolling-review-for-ost-her2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/os-therapies-gains-ema-rolling-review-for-ost-her2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4081","OST","EMA","BK4148","OSTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631902435","title":"Press Release: Teva Delivers Strong Q1 2026 Results Driven by Innovative Portfolio Growth and Disciplined Execution","url":"https://stock-news.laohu8.com/highlight/detail?id=2631902435","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631902435?lang=en_us&edition=fundamental","pubTime":"2026-04-29 19:00","pubTimestamp":1777460400,"startTime":"0","endTime":"0","summary":"For an accessible version of this Press Release, please visit www.tevapharm.com. -- Q1 2026 revenues of $4.0 billion increased by 2% in U.S. dollars. year-over-year , and decreased by 3% in local currency terms .Excluding the Japan business venture  results, revenues decreased by. 1% in LC. These strong first quarter results were driven by our. innovative portfolio growth and disciplined execution, even with lower. due to increased generic competition in the U.S.-- Key Innovative brands continued to drive growth and provide value for. patients, while transforming Teva's portfolio mix and financial profile:. -- AUSTEDO continued to show strong growth, with global revenues. of $578 million, growing 41% YoY in LC.-- AJOVY global revenues of $196 million, increased by 35% YoY in. -- UZEDY revenues of $63 million, increased by 62% YoY in LC.Fastest growing long-acting injectable 1 has nearly doubled. -- Collectively these brands' revenues grew by 41% YoY in LC.-- Generics revenues are lower","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4120","BK4232","BK4116","03160","MAA","BK4081","LU1861220207.SGD","LU2360107671.USD","BK4099","BK4596","BK4584","EMA","LU2324357040.USD","BK4166","BK4023","LC","R","BK4007","CD","TM","LU1983299246.USD","BK4585","BV","BK4215","BK4555","TEVA","BK4022","BK4557","LU1861217088.USD","BK4604","BK4566","BK4588","BK4559"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630209377","title":"Emera Inc : Barclays Initiates Coverage With Equal-Weight  Rating  and Target Price $53","url":"https://stock-news.laohu8.com/highlight/detail?id=2630209377","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630209377?lang=en_us&edition=fundamental","pubTime":"2026-04-28 18:17","pubTimestamp":1777371445,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nFWN41B0JH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EMA","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630377020","title":"Emera initiated with an Equal Weight at Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2630377020","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630377020?lang=en_us&edition=fundamental","pubTime":"2026-04-28 18:16","pubTimestamp":1777371399,"startTime":"0","endTime":"0","summary":"Barclays initiated coverage of Emera (EMA) with an Equal Weight rating and $53 price target The firm believes the company’s premium Florida regulat...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/emera-initiated-with-an-equal-weight-at-barclays-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/emera-initiated-with-an-equal-weight-at-barclays-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4081","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630225347","title":"Analysts Have Conflicting Sentiments on These Utilities Companies: Emera (EMA), Origin Energy Limited (OtherOGFGF) and Clearway Energy (CWEN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2630225347","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630225347?lang=en_us&edition=fundamental","pubTime":"2026-04-28 09:50","pubTimestamp":1777341028,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Utilities sector with new ratings on Emera (EMA), Origin Energy Limited (OGFGF) and Clearway Energy (CW...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-utilities-companies-emera-ema-origin-energy-limited-otherogfgf-and-clearway-energy-cwen-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-utilities-companies-emera-ema-origin-energy-limited-otherogfgf-and-clearway-energy-cwen-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EMA","IE00BZ18W456.USD","BK4105","OGFGF","IE00BMQBXF63.USD","IE00BZ18W340.USD","CWEN","BK4133","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630343317","title":"A Look At Arrowhead Pharmaceuticals (ARWR) Valuation After EMA CHMP Backs REDEMPLO For FCS","url":"https://stock-news.laohu8.com/highlight/detail?id=2630343317","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630343317?lang=en_us&edition=fundamental","pubTime":"2026-04-28 05:06","pubTimestamp":1777324015,"startTime":"0","endTime":"0","summary":"Arrowhead Pharmaceuticals (ARWR) is back in focus after the EMA’s Committee for Medicinal Products for Human Use issued a positive opinion on REDEMPLO, its siRNA therapy for familial chylomicronemia syndrome in Europe.\nSee our latest analysis for Arrowhead Pharmaceuticals.\nThe CHMP opinion comes after a powerful run in the shares, with a 1 month share price return of 27.92% and a 7 day gain of 6.73%. The 1 year total shareholder return is very large, suggesting momentum has been building...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arwr/arrowhead-pharmaceuticals/news/a-look-at-arrowhead-pharmaceuticals-arwr-valuation-after-ema","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arwr/arrowhead-pharmaceuticals/news/a-look-at-arrowhead-pharmaceuticals-arwr-valuation-after-ema","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CHMP","BK4081","BK4087","BK4139","DCF","BK4585","EMA","BK4588","ARWR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630435456","title":"Novartis Rhapsido® receives European Commission approval as first oral targeted treatment for chronic spontaneous urticaria","url":"https://stock-news.laohu8.com/highlight/detail?id=2630435456","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630435456?lang=en_us&edition=fundamental","pubTime":"2026-04-27 13:15","pubTimestamp":1777266900,"startTime":"0","endTime":"0","summary":"Significant improvements as early as Week 1,favorable safety profileand no liversafetyconcerns in REMIX 1 & 2studies of highly selective, oral BTKi1Rhapsidorecommended in2026 InternationalUrticaria Gu","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/27/3281278/0/en/Novartis-Rhapsido-receives-European-Commission-approval-as-first-oral-targeted-treatment-for-chronic-spontaneous-urticaria.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CHMP","EC","BK4081","EMA","BK4087","BK4201"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630333203","title":"Clinuvel Unlikely to Seek Scenesse's Vitiligo Approval Before Phase 3 Completion, Says Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2630333203","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630333203?lang=en_us&edition=fundamental","pubTime":"2026-04-27 08:14","pubTimestamp":1777248895,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals  is unlikely to seek regulatory approval for Scenesse in vitiligo until the Phase 3 CUV105 and CUV107 clinical trials are completed, according to a Friday Jefferies note.The company said on Friday that the European Medicines Agency  has proposed evaluating the company's Scenesse drug for the treatment of systemic vitiligo based on a \"totality of evidence\" regulatory approach.Jefferies said that the EMA's decision is a positive for the company because of the high unmet medical need for Vitiligo treatment.The investment firm has pushed back its revenue expectations from Scenesse in vitiligo, which is now expected to begin in the second half of fiscal 2029 rather than fiscal 2028.Jefferies kept a buy rating on Clinuvel and cut its price target to AU$39.20 from AU$40.50.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK7508","EMA","CUV.AU","BK4081","BK7129","EMA.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630337810","title":"PYC Wins EMA Orphan Status for RP11 Gene Therapy Candidate VP-001","url":"https://stock-news.laohu8.com/highlight/detail?id=2630337810","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630337810?lang=en_us&edition=fundamental","pubTime":"2026-04-27 08:07","pubTimestamp":1777248433,"startTime":"0","endTime":"0","summary":"PYC Therapeutics Limited ( ($AU:PYC) ) has provided an announcement. PYC Therapeutics has secured Orphan Drug Designation from the European Medicin...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/pyc-wins-ema-orphan-status-for-rp11-gene-therapy-candidate-vp-001?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/pyc-wins-ema-orphan-status-for-rp11-gene-therapy-candidate-vp-001?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4081","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630803936","title":"J.P. Morgan Reaffirms Their Hold Rating on Emera (EMA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2630803936","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630803936?lang=en_us&edition=fundamental","pubTime":"2026-04-25 20:21","pubTimestamp":1777119687,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Eli Jossen from J.P. Morgan maintained a Hold rating on Emera, with a price target of C$73.00. The company’s shares...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/j-p-morgan-reaffirms-their-hold-rating-on-emera-ema-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/j-p-morgan-reaffirms-their-hold-rating-on-emera-ema-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630980518","title":"How Investors Are Reacting To Clinuvel Pharmaceuticals (ASX:CUV) EMA Guidance On SCENESSE Vitiligo Trial Design","url":"https://stock-news.laohu8.com/highlight/detail?id=2630980518","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630980518?lang=en_us&edition=fundamental","pubTime":"2026-04-25 20:10","pubTimestamp":1777119025,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals recently reported that the European Medicines Agency issued final scientific advice on its planned pivotal Phase III CUV107 trial, outlining how SCENESSE (afamelanotide) will be evaluated as a systemic treatment for non-segmental vitiligo in adults and adolescents.\nThe regulator’s “totality of evidence” approach, with T-VASI50 as the primary endpoint and strong emphasis on patient-reported and photographic outcomes, underscores both the complexity and patient-centric...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cuv/clinuvel-pharmaceuticals-shares/news/how-investors-are-reacting-to-clinuvel-pharmaceuticals-asxcu-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cuv/clinuvel-pharmaceuticals-shares/news/how-investors-are-reacting-to-clinuvel-pharmaceuticals-asxcu-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4588","ARTY","BK4543","EMA","BK4211","AIPO","AGIX","BK4023","BK7508","BK4528","BK7067","ISBC","CHAT","BK4585","BK4551","AI","BK4587","CUV.AU","AIYY","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629810110","title":"Novartis receives positive CHMP opinion for Itvisma® for spinal muscular atrophy (SMA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2629810110","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629810110?lang=en_us&edition=fundamental","pubTime":"2026-04-24 18:30","pubTimestamp":1777026600,"startTime":"0","endTime":"0","summary":"If approved, Itvisma (intrathecal onasemnogeneabeparvovec) will be first and only gene replacement therapy for children two years and older, teens and adults with SMA in the European UnionItvisma demo","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/24/3280652/0/en/Novartis-receives-positive-CHMP-opinion-for-Itvisma-for-spinal-muscular-atrophy-SMA.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CHMP","LU0528227936.USD","LU1989772923.USD","LU2089283258.USD","LU2133065610.SGD","BK4127","BK4585","SMA","LU0557290698.USD","LU2357305700.SGD","LU1668664300.SGD","LU1989772840.SGD","LU0106831901.USD","LU1162221912.USD","LU1791710582.SGD","LU2023251221.USD","LU1732800096.USD","LU0234570918.USD","BK4516","LU0098860793.USD","LU1720051017.SGD","LU0225283273.USD","LU2111349929.HKD","BK4588","LU0795875086.SGD","LU0267386448.USD","LU1791710400.SGD","LU0795875169.SGD","LU1363072403.SGD","LU0882574139.USD","LU2089284900.SGD","LU1720051108.HKD","LU2271345857.HKD","BK4081","LU1244550577.SGD","BK4087","LU0106261372.USD","EMA","EC","LU2028103732.USD","BK4201","BK4581","LU0971096721.USD","LU1548497426.USD","LU0320765646.SGD","IE00BKVL7J92.USD","LU0912757837.SGD","NORD","LU0006306889.USD","LU1244550221.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629812635","title":"Ema: Chmp Recommended Extensions of Indication for Nine Medicines Including Comirnaty","url":"https://stock-news.laohu8.com/highlight/detail?id=2629812635","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629812635?lang=en_us&edition=fundamental","pubTime":"2026-04-24 17:51","pubTimestamp":1777024282,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260424:nFWN4161D9:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0122379950.USD","LU0306807586.USD","BK4585","IE0002270589.USD","IE00B19Z3581.USD","LU1066053197.SGD","LU1894683264.USD","IE000M9KFDE8.USD","LU0306806265.USD","LU1023059063.AUD","LU1894683348.USD","LU0234572021.USD","LU0868494617.USD","LU1883839398.USD","BK4581","BK4568","IE00B19Z3B42.SGD","LU1057294990.SGD","SG9999001176.USD","SG9999003800.SGD","LU0170899867.USD","LU0321505868.SGD","BK4592","SGXZ57979304.SGD","BK4550","PFE","IE00BBT3K403.USD","SG9999002224.SGD","SG9999011175.SGD","SG9999001176.SGD","BK4588","BK4534","LU0456855351.SGD","LU0058720904.USD","LU0321505439.SGD","SG9999013999.USD","LU0289739699.SGD","EMA","IE00BLSP4452.SGD","BK4007","BK4533","BK4599","LU1066051498.USD","LU0225771236.USD","LU0225284248.USD","LU0985481810.HKD","IE00BLSP4239.USD","SG9999002232.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629926808","title":"CLINUVEL receives final EMA scientific advice for pivotal Phase III vitiligo study","url":"https://stock-news.laohu8.com/highlight/detail?id=2629926808","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629926808?lang=en_us&edition=fundamental","pubTime":"2026-04-24 13:47","pubTimestamp":1777009620,"startTime":"0","endTime":"0","summary":"“Totality of evidence” approach to evaluate SCENESSEEXECUTIVE SUMMARY final European scientific advice received for pivotal Phase III vitiligo studyEMA emphasised its “totality of evidence” approachce","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/24/3280522/0/en/CLINUVEL-receives-final-EMA-scientific-advice-for-pivotal-Phase-III-vitiligo-study.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4582","III","BK4087","EPP","CHMP","CFB","EMA","BK4081","BK4211","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629862958","title":"Clinuvel Pharmaceuticals Set for Phase 3 Vitiligo Study After Final Advice From European Medicines Agency","url":"https://stock-news.laohu8.com/highlight/detail?id=2629862958","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629862958?lang=en_us&edition=fundamental","pubTime":"2026-04-24 08:10","pubTimestamp":1776989406,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals (ASX:CUV) said the European Medicines Agency (EMA) has proposed evaluating the company's Scenesse drug for the treatment of systemic vitiligo based on a \"totality of evidence\"","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4081","EMA.AU","EMA","MDCO","BK7067","CUV.AU","BK7508","BK7129"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629651864","title":"Clinuvel Secures EMA Guidance for Pivotal Vitiligo Trial of SCENESSE","url":"https://stock-news.laohu8.com/highlight/detail?id=2629651864","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629651864?lang=en_us&edition=fundamental","pubTime":"2026-04-24 07:14","pubTimestamp":1776986084,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals ( ($AU:CUV) ) has issued an announcement. Clinuvel Pharmaceuticals has received final scientific advice from the European ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/clinuvel-secures-ema-guidance-for-pivotal-vitiligo-trial-of-scenesse?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/clinuvel-secures-ema-guidance-for-pivotal-vitiligo-trial-of-scenesse?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4081","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629009215","title":"Press Release: Ipsen delivers strong sales in the first quarter of 2026 and confirms its full-year guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2629009215","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629009215?lang=en_us&edition=fundamental","pubTime":"2026-04-23 13:00","pubTimestamp":1776920400,"startTime":"0","endTime":"0","summary":"-- Total sales growth of 22.6% at CER1 or 17.0% as reported, driven by all. three therapeutic areas, with accelerating portfolio momentum outside. -- Strong pipeline momentum with three Phase III readouts expected in H2. PARIS, FRANCE, 23 April 2026 - Ipsen , a global specialty-care biopharmaceutical company, today presents its sales for the first quarter of 2026.\"Ipsen has delivered a strong start to 2026,\" said David Loew, Chief Executive Officer, Ipsen. \"We advanced our strategic priorities across the business, combining strong top--line performance with continued pipeline progress. I am very pleased with the growth of our rare liver disease franchise with the performance of Iqirvo and Bylvay. Additionally, with three Phase III readouts expected this year and three new late-stage programs starting, Ipsen is well-positioned to drive sustainable growth and deliver meaningful value for patients.\". Ipsen is confirming its financial guidance for full-year 2026:. Ipsen anticipates several","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4087","BK4201","BK4081","R","CHMP","BK4232","BK4022","EMA","EC"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":9,"totalSize":200,"code":"91000000","status":"200"}]}}